| Trial ID: | L3945 |
| Source ID: | NCT00615212
|
| Associated Drug: |
Gsk376501
|
| Title: |
Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GSK376501|DRUG: Midazolam|DRUG: Rosiglitazone|DRUG: Flurbiprofen
|
| Outcome Measures: |
Primary: drug plasma levels midazolam:, Days 1 & 11|drug plasma levels rosiglitazone:, Days 2 & 12|drug plasma levels flurbiprofen:, Days 3 & 13 | Secondary: adverse reactions,changes in laboratory values,changes in vital signs, & ECG changes:, Days 1-13|drug plasma levels GSK376501:, Days 4-13|Safety and tolerability during dosing with GSK376501, alone and in combination with the various probe substrates., Up to Day 24|Daily predose trough GSK376501 plasma concentrations when administered alone for 7 days (Days 4-13)., for 7 days (Days 4-13).
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
23
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-01-02
|
| Completion Date: |
2008-02-15
|
| Results First Posted: |
|
| Last Update Posted: |
2017-09-11
|
| Locations: |
GSK Investigational Site, Buffalo, New York, 14202, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00615212
|
